Conference – The Health of Women – Day 1
VirtualCardiovascular Symposium Theme: “Cutting Edge Topics in Cardiovascular Disease in Women” - Day 1
Cardiovascular Symposium Theme: “Cutting Edge Topics in Cardiovascular Disease in Women” - Day 1
Name the pharmaceuticals that have been FDA approved for treatment of alcohol use disorder. Understand the potential benefits and side effects of medications for alcohol use disorder. Know the number needed to treat (NNT) medications for alcohol use disorder and how they compare with other typical primary care treatments.
All Oregon clinicians are encouraged to register for these weekly interactive sessions to learn the latest information on best practices in clinical management, clinical practice safety, testing, and the community public health response. Register here for the ECHO COVID series (January 7-June 17): https://connect.oregonechonetwork.org/Series/Registration/1335 Drop-in connection details (no CME): https://echo.zoom.us/j/2382480348?pwd=d1dGS3lIeUt6QXRWR3p4d2x3VFlQUT09 Password: 874887 • Hosted by […]
Cardiovascular Symposium Theme: “Cutting Edge Topics in Cardiovascular Disease in Women” - Day 2
The OHA Transformation Center, in partnership with the OHA Vaccine Planning Unit, is hosting a learning collaborative for clinics newer to COVID immunizations to learn from subject matter experts and health center peers. Topics such as operational workflows, allocations, targeting high risk populations, vaccine hesitancy and more will be covered.
VBP and maternity care: What have we learned so far?
General Women's Health & GYN Symposium
Apply quality improvement frameworks and tools for measurable change in diabetes, HBA1C poor control and oral health evaluation for adults with diabetes. Join this hour-long live webinar, led by ORPRN practice facilitators who will walk through how to use the new toolkit in primary care and dental clinical settings and answer your questions. This new […]
Review the impact of COVID-19 on screening for AUD and other mental health disorders. Discuss benefits and limitations to using telehealth to engage patients in screening and intervention. Identify possible workflow approaches for screening during telehealth visits. Review considerations for the future.
OHA will hold REALD office hours to answer questions from phase 2 providers about Race, Ethnicity, Language, and Disability (REALD) data collection and reporting requirements during health care encounters for COVID-19.